Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00116103 · ClinicalTrials.gov registry record · Phase 2

A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma

A Phase 2 study of Asthma, sponsored by Astellas Pharma.

Completed
Registry status
Phase 2
Development phase
20
Study locations

NCT00116103 is a Phase 2 study of Asthma that has completed, run by Astellas Pharma. The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00116103, a Phase 2 study of Asthma, has completed, sponsored by Astellas Pharma.

COMPLETED
Registry status
Phase 2
Development phase
20
Study locations

Study Summary

The purpose of this study is to determine the safety and effectiveness of tacrolimus inhalation aerosol in subjects with persistent asthma.

Conditions Studied

Asthma

Interventions

  • DRUG Tacrolimus Inhalation Aerosol

Study Locations (20)

California

  • - Encinitas
  • - Los Angeles
  • - San Diego
  • - San Jose

Florida

  • - Daytona Beach
  • - Miami

Arizona

  • - Scottsdale

Colorado

  • - Denver

Idaho

  • - Boise

Illinois

  • - River Forest

Indiana

  • - South Bend

Missouri

  • - St Louis

Trial Details

FieldValue
Start Date 2005-06
Est. Completion 2006-04
Phase Phase 2

Sponsor

Astellas Pharma

165 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00116103

The ClinicalTrials.gov registry entry for NCT00116103 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Tacrolimus Inhalation Aerosol is the first listed.

NCT00116103 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT00116103 about?

NCT00116103 is a clinical study titled "A Study of the Safety and Efficacy of Tacrolimus Inhalation Aerosol in Subjects With Persistent Asthma". The purpose of this study is to determine the safety and effectiveness of tacrolimus inhalation aerosol in subjects with persistent asthma.

What is the current status of trial NCT00116103?

This trial is currently completed. It is a Phase 2 study. The study started on 2005-06. Estimated completion is 2006-04.

What conditions does trial NCT00116103 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT00116103?

The interventions under investigation include: Tacrolimus Inhalation Aerosol (DRUG).

Who is sponsoring clinical trial NCT00116103?

This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00116103 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.